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with the inflammatory markers procalcitonin (0.20, 95% CI 
0.03–0.37), proadrenomedullin (0.28, 95% CI 0.12–0.43) and 
albumin (–0.39, 95% CI –0.57 to –0.21), the stress marker co-
peptin (0.34, 95% CI 0.17–0.51), the renal function marker 
urea (0.23, 95% CI 0.07–0.38), the nutritional markers vitamin 
D25 (–0.22, 95% CI –0.41 to –0.02) and corrected calcium 
(0.29, 95% CI 0.10–0.49) and the hematological markers he-
moglobin (–0.27, 95% CI –0.43 to –0.10) and red blood cell 
distribution width (0.26, 95% CI 0.07–0.44). Subgroup analy-
sis suggested that acute malnutrition rather than chronic 
malnutrition was associated with elevated biomarker levels. 
 Conclusion: Acute malnutrition was associated with a pro-
nounced inflammatory response and an alteration in bio-
markers associated with different pathophysiological states. 
Interventional trials are needed to prove causality. 
 © 2016 S. Karger AG, Basel 
 Key Words 
 Malnutrition · Outcomes · Biomarker · Hospitalization · 
Nutrition screening 
 Abstract 
 Background and Aims: Malnutrition is associated with poor 
clinical outcomes. Whether there is a causal relationship or 
it merely mirrors a severe patient condition remains unclear. 
We examined the association of malnutrition with biomark-
ers characteristic of different pathophysiological states to 
better understand the underlying etiological mechanisms. 
 Methods: We prospectively followed consecutive adult 
medical inpatients. Multivariable regression models were 
used to investigate the associations between malnutrition – 
as assessed using the Nutritional Risk Screening (NRS 2002) – 
and biomarkers linked to inflammation, stress, renal dys-
function, nutritional status and hematologic function.  Re-
sults: A total of 529 patients were included. In a fully 
adjusted model, malnutrition was significantly associated 
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 Introduction 
 Malnutrition is a frequent problem in hospitalized 
medical patients and may result from chronic diseases, 
which lead to cachexia and weight loss, or acute illness, 
which decreases appetite and nutritional intake. Approx-
imately 30% of patients hospitalized on medical wards are 
at risk nutritionally, with available evidence suggesting 
that these patients have poorer clinical outcomes exem-
plified by higher rates of morbidity and mortality as well 
as prolonged hospital stays  [1, 2] . There is thus a clear 
need for proactive screening and management of malnu-
trition in the hospital setting. Screening for malnutrition 
in adult inpatients is best accomplished following the Nu-
tritional Risk Screening (NRS) 2002 guidelines published 
by the European Society for Clinical Nutrition and Me-
tabolism (ESPEN)  [3] . These guidelines permit the cate-
gorization of a patient’s impaired nutritional status tak-
ing into consideration the severity of disease.
 Despite the high prevalence of malnutrition in the 
hospital setting, the underlying pathophysiologic mech-
anisms and their impact on laboratory findings are still 
incompletely understood  [4, 5] . Earlier studies in this 
area attribute a central role for cytokines in the patho-
genesis of cachexia, particularly cancer cachexia. Cyto-
kines are an integral part of the systemic inflammatory 
response and have been implicated in the etiology of an-
orexia, weight loss, cognitive dysfunction, anemia and 
frailty. They induce ubiquitin-mediated proteolysis that 
releases amino acids, which are then used for the hepatic 
production of C-reactive protein (CRP)  [6] . Cytokines 
are also implicated in an imbalance of stress hormones, 
with increased glucocorticoid hormones and decreased 
sexual hormones potentially contributing to catabolism 
 [7] . Furthermore, recent studies have suggested the oc-
currence of cross talk between inflammatory cytokines 
and glucagon-like peptide-1 (GLP-1), reducing food in-
take and inducing weight loss  [8] . These diverse path-
ways are thought to synergistically play a role in (cancer) 
cachexia, which has been characterized by the ESPEN as 
a systemic pro-inflammatory process that results in met-
abolic derangements that include insulin resistance, loss 
of body fat and muscle and increased lipolysis, lipid oxi-
dation, protein turnover and production of acute phase 
proteins  [9] .
 Inflammation in acutely and chronically ill patients is 
thought to influence nutritional status. Conversely, di-
etary factors also have an impact on the inflammatory 
response and clinical outcomes. This bidirectional rela-
tionship is complex and currently incompletely under-
stood. Whether malnutrition has a direct link to adverse 
outcomes or is instead a mirror of disease severity re-
mains unclear. Herein, our aim was to study whether 
acute and chronic malnutrition as assessed with the NRS 
2002 is associated with blood biomarkers of inflamma-
tion/infection, stress and kidney and hematological func-
tion. We also investigated whether these associations re-
mained robust after rigorous adjustment for disease se-
verity and other potential confounding factors in 
multivariate regression models.
 Methods 
 Study Design 
 This secondary observational analysis included consecutive 
medical inpatients hospitalized through the emergency depart-
ment (ED) of a Swiss tertiary care hospital between February 2013 
and October 2013. All patients were participants in a prospective, 
observational, multicenter, multinational trial called the TRIAGE 
project that aimed to devise an algorithm to optimize triage and 
anticipate the post-acute care needs of adult patients with medical 
emergencies  [10] . The institutional review board waived the need 
for informed consent because of the observational nature of the 
study (through notification EK 2012/059).
 Patient Population and Management of Patients 
 We used patient data from the TRIAGE project cohort hospi-
talized during the defined time period (3,585 patients). Five hun-
dred twenty-nine of these patients met inclusion criteria, which 
included manifest or imminent risk of development of malnutri-
tion as well as availability of NRS scores and all laboratory values. 
Data on main diagnosis of each patient and left over blood samples 
were collected from the ED. During their hospital stay, the pa-
tients’ clinical information including their sociodemographic data 
was collected, and comorbidities were assessed prospectively. 
Nursing staff assessed nutritional status using NRS 2002 guidelines 
within 48 h after hospital admission.
 Definitions of Main Diagnosis and Comorbidities 
 The main diagnosis was assigned to different groups using di-
agnosis-related group codes. Generated groups included infec-
tious diseases, tumors, cardiovascular disease, pulmonary disease, 
gastrointestinal disease, immune disorders, endocrine disorders, 
neurological disorders, psychological disorders/intoxication, 
musculoskeletal disorders and ‘other’ main diagnoses. Comorbid-
ities were also grouped in a similar manner.
 Outcome Measures 
 The end point in this study was the association of NRS scores 
with biomarkers associated with different pathophysiological 
states. At the time of admission, we measured CRP, procalcitonin 
(PCT), white blood cell (WBC) count, albumin and proadreno-
medullin  (proADM) to reflect inflammatory or infectious process-
es; copeptin as a stress marker; creatinine and urea as indicators of 
renal function; vitamin D25, corrected calcium and glucose as nu-
tritional markers; and platelets, international normalized ratio 
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(INR), hemoglobin and red blood cell distribution width (RDW) 
as indicators of hematological function.
 The following markers were measured as part of routine 
care: CRP (normal value  ≤ 0.3 mg/l), WBC (normal range 4.0–
10.0 × 10 9 /l), albumin (normal range 34.0–50.0 g/l), creatinine 
(normal range 71.0–115.0 μmol/l), urea (normal range 2.0–7.0 
mmol/l), 25(OH) vitamin D (normal range 50.0–250.0 nmol/l), 
corrected calcium (normal range 2.15–2.55 mmol/l), glucose 
(normal range [fasting] 3.9–5.5 mmol/l), platelet counts (nor-
mal range 140–400/mm 3 ), INR (normal range 2.0–3.5), hemo-
globin (normal range 135.0–172.0 g/l) and RDW (normal range 
 ≤ 15.0%).
 In addition, we measured PCT levels post hoc using an auto-
mated rapid sensitive assay (the KRYPTOR PCT assay produced 
by Thermo Scientific Biomarkers (formerly B.R.A.H.M.S AG), 
Hennigsdorf, Germany; normal range  ≤ 0.50 μg/l and detection 
limit 0.02 μg/l). Concentrations of ProADM were batch-measured 
in plasma using an automated sandwich chemiluminescence im-
munoassay on the KRYPTOR system (detection limit 0.05 nmol/l). 
Copeptin (normal range <19.0 pmol/l and detection limit 0.9 
pmol/l) was detected in stored EDTA plasma samples of all pa-
tients with a new sandwich immunoassay (B.R.A.H.M.S Sevapres-
sin ® LIA, B.R.A.H.M.S AG, Hennigsdorf, Germany).
 Assessment of Nutritional Status and Definition of Nutritional 
Impairment 
 Nutritional status was assessed using the NRS 2002, a screening 
tool that considers nutritional status (1–3 points), severity of ill-
ness (1–3 points) and age (one point if age >70 years). As recom-
mended in the original publication by Kondrup et al.  [11] , a NRS 
score  ≥ 3 was designated as a cutoff for malnutrition or risk of de-
veloping malnutrition. The NRS score includes measures of both 
acute (reduced food intake during the last week) and chronic (low 
BMI, indicative of weight loss over a 3-month period) malnutri-
tion. In recognition of this, we classified malnutrition seen in the 
patients in this study as being acute or chronic.
 Statistical Analysis 
 The association between NRS scores and biomarker levels was 
assessed with patients being categorized into 3 groups based on 
NRS scores: NRS <3, NRS = 3 and NRS >3. Patient characteristic 
variables are expressed as medians (interquartile ranges [IQR; 
25th–75th percentiles]), while frequencies are reported as percent-
ages. Patient characteristics were compared using the chi-square 
test for binary data and analysis of variance for continuous data 
across the 3 NRS groups. Biomarker levels are graphically depicted 
in  figure 1 . For ease of comparison during further analyses, labora-
tory values were transformed into deciles. The association between 
NRS scores and laboratory findings was explored using linear re-
gression analyses, with results being reported as coefficients with 
95% CIs. Additionally, we adjusted for age and gender (Model 1); 
age, gender and comorbidities (Model 2); and age, gender, comor-
bidities and main diagnosis (Model 3). Furthermore, we conduct-
ed a subgroup analysis in which acutely and chronically malnour-
ished patients were studied separately. Patients with concomitant 
acute malnutrition and chronic weight loss were excluded from the 
subgroup analyses. All statistical analyses were performed using 
the STATA 12.1 software package (StataCorp, College Station, 
Tex., USA). A p value <0.05 (for a 2-sided test) was considered sta-
tistically significant.
 Results 
 Patient Population 
 Of 529 patients meeting the inclusion criteria, 350 
(66.2%) had no nutritional impairment, while 179 
(33.8%) were nutritionally at risk, with NRS scores of 3 
points (91, 17.2%) or higher (88, 16.6%). Baseline char-
acteristics of the study cohort according to NRS score are 
shown in  table 1 . Two hundred twenty-seven (42.9%) pa-
tients were women, and their median age was 72 years 
(IQR 62–80). Patients at risk nutritionally were signifi-
cantly older (ages 69 vs. 73 vs. 73 years for patients with 
NRS scores less than, equal to or greater than 3, respec-
tively; p < 0.001) and suffered more often from tumors 
and gastrointestinal diseases but less often from cardio-
vascular diseases.
 Laboratory Findings 
 Patients at risk nutritionally showed significantly 
higher CRP levels (70.6 vs. 83.4 vs. 103.5 mg/l, p = 0.027), 
PCT levels (0.16 vs. 0.21 vs. 0.24 μg/l, p = 0.007) and pro-
ADM levels (1.34 vs. 1.62 vs. 1.62 nmol/l, p  = 0.001). 
There was no significant difference in WBC counts be-
tween the 3 groups (10.31 vs. 9.66 vs. 10.61 × 10 9 /l, p = 
0.54). Albumin was lower in patients nutritionally at risk 
(33.4 vs. 31.4 vs. 28.9 g/l, p < 0.001). Copeptin, a stress 
marker, was present at higher levels in these patients (24.7 
vs. 40.0 vs. 53.5 pmol/l, p < 0.001). Renal function differed 
as measured by urea levels (6.6 vs. 7.9 vs. 8.0 mmol/l, p = 
0.036), but not in terms of creatinine levels (99.0 vs. 97.0 
vs. 95.5 μmol/l, p = 0.530). Surprisingly, corrected calci-
um was present at higher levels in malnourished patients 
(2.33 vs. 2.39 vs. 2.42 mmol/l, p < 0.001), while both glu-
cose (6.7 vs. 6.7 vs. 6.6 mmol/l, p = 0.870) and vitamin 
D25 (43.3 vs. 32.6 vs. 36.3 nmol/l, p = 0.060) showed no 
significant aberrations. Hemoglobin was significantly 
lower (128.5 vs. 122.0 vs. 117.5 g/l, p < 0.001) and RDW 
was significantly higher (14.0 vs. 15.3 vs. 15.0%, p < 0.001) 
in patients with NRS scores  ≥ 3. Patients’ platelet counts 
or INR values did not differ significantly between the 3 
groups. Laboratory findings (median and 75th percen-
tile) of the 3 patient groups are visually represented in 
 figure 1 .
 Association of NRS Scores with Biomarker Levels 
 We performed linear regression analyses (regression 
coefficient, 95% CI, p value) and found a stepwise in-
crease of inflammation/infection biomarkers (CRP 0.21, 
95% CI 0.03–0.39, p = 0.021; PCT 0.28, 95% CI 0.10–0.47, 
p = 0.003; proADM 0.40, 95% CI 0.23–0.58, p < 0.001; 
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albumin –0.60, 95% CI –0.77 to –0.43, p < 0.001) in pa-
tients with NRS scores <3, 3 and >3 points, with the ex-
ception of WBC counts (–0.04, 95% CI –0.22 to 0.14, p = 
0.630). Higher NRS scores were also associated with 
higher copeptin (0.44, 95% CI 0.27–0.62, p < 0.001) and 
urea (0.28, 95% CI 0.10–0.46, p = 0.002) levels. Findings 
were similar with regard to lower levels of vitamin D25 
(–0.23, 95% CI –0.41 to –0.05, p = 0.012) as well as high-
er levels of corrected calcium (0.43, 95% CI 0.26–0.61, 
p < 0.001). No significant association was found for glu-
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 Fig. 1. Median biomarker levels categorized by NRS score (bars represent medians and error bars identify the 75th percentile). 
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Table 1.  Patient characteristics categorized by NRS scores
Characteristic Overall NRS <3 NRS = 3 NRS >3 p value
n (%) 529 (100) 350 (66.2) 91 (17.2) 88 (16.6)
Sociodemographics
Female gender, n (%) 227 (42.9) 151 (43.1) 35 (38.5) 41 (46.6) 0.540
Age, years, median (IQR) 72 (62–80) 69 (60–79) 73 (65–83) 73 (68–80) 0.009
Main diagnosis, n (%)
Infectious disease 211 (39.9) 137 (39.1) 39 (42.9) 35 (39.8) 0.810
Tumor/malignancy 56 (10.6) 21 (6.0) 16 (17.6) 19 (21.6) <0.001
Cardiovascular disease 85 (16.1) 66 (18.9) 14 (15.4) 5 (5.7) 0.011
Pulmonary disease 69 (13.0) 47 (13.4) 10 (11.0) 12 (13.6) 0.810
Gastrointestinal disease 30 (5.7) 16 (4.6) 4 (4.4) 10 (11.4) 0.041
Immune/inflammatory disorder 9 (1.7) 6 (1.7) 2 (2.2) 1 (1.1) 0.860
Endocrine disorder 9 (1.7) 7 (2.0) 1 (1.1) 1 (1.1) 0.760
Neurological disorder 11 (2.1) 8 (2.3) 1 (1.1) 2 (2.3) 0.770
Psychological disorder/intoxication 9 (1.7) 7 (2.0) 0 (0.0) 2 (2.3) 0.380
Musculosceletal disorder 20 (3.8) 18 (5.1) 1 (1.1) 1 (1.1) 0.072
Other 18 (3.4) 15 (4.3) 3 (3.3) 0 (0.0) 0.140
Comorbidities, n (%)
Infectious disease 340 (64.3) 219 (62.6) 59 (64.8) 62 (70.5) 0.380
Tumors 152 (28.7) 76 (21.7) 35 (38.5) 41 (46.6) <0.001
Cardiovascular disease 376 (71.1) 260 (74.3) 62 (68.1) 54 (61.4) 0.046
Chronic obstructive pulmonary disease 89 (16.8) 58 (16.6) 16 (17.6) 15 (17.0) 0.970
Anemia 137 (25.9) 80 (22.9) 28 (30.8) 29 (33.0) 0.078
Endocrine disorder 308 (58.2) 209 (59.7) 51 (56.0) 48 (54.5) 0.610
Renal disease 159 (30.1) 108 (30.9) 28 (30.8) 23 (26.1) 0.680
Other 169 (31.9) 107 (30.6) 27 (29.7) 35 (39.8) 0.220
Biomarkers, median (IQR)
Inflammation/infection
CRP, mg/l 80.5 (22.4–150.0) 70.6 (20.3–141.0) 83.4 (27.0–155.0) 103.5 (40.0–160.0) 0.027
PTC, μg/l 0.19 (0.11–0.53) 0.16 (0.11–0.47) 0.21 (0.12–0.48) 0.24 (0.13–2.11) 0.007
WBC, 109/l 10.31 (7.27–14.03) 10.31 (7.50–14.04) 9.66 (6.82–14.00) 10.61 (6.39–14.08) 0.540
Albumin, g/l 32.3 (28.5–36.2) 33.4 (29.6–36.8) 31.4 (28.4–34.3) 28.9 (25.6–33.8) <0.001
ProADM, nmol/l 1.44 (1.02–2.37) 1.34 (0.99–2.03) 1.62 (1.17–2.84) 1.62 (1.07–2.84) 0.001
Stress
Copeptin, pmol/l 31.1 (9.8–77.0) 24.7 (8.5–67.7) 40.0 (14.4–106.0) 53.5 (24.8–90.6) <0.001
Renal function
Creatinine, μmol/l 98.0 (78.0–139.0) 99.0 (80.0–133.0) 97.00 (73.0–155.0) 95.5 (70.5–139.0) 0.530
Urea, mmol/l 7.0 (4.9–11.6) 6.6 (4.7–10.9) 7.9 (5.6–13.2) 8.0 (5.2–13.5) 0.036
Nutritional status
Vitamin D25, nmol/l 41.0 (22.9–67.5) 43.3 (24.1–69.5) 32.6 (22.2–63.2) 36.3 (19.5–69.5) 0.060
Calcium corrected, mmol/l 2.35 (2.26–2.46) 2.33 (2.26–2.43) 2.39 (2.27–2.50) 2.42 (2.31–2.51) <0.001
Glucose, mmol/l 6.7 (5.8–8.2) 6.7 (5.8–8.2) 6.7 (5.7–8.2) 6.6 (5.7–8.3) 0.870
Hematological function
Platelets, /mm3 223.0 (171.0–296.0) 225.0 (176.0–294.0) 213.0 (148.0–299.0) 229.5 (171.5–303.5) 0.530
INR 1.2 (1.1–1.4) 1.2 (1.1–1.4) 1.2 (1.1–1.3) 1.2 (1.1–1.3) 0.840
Hemoglobin, g/l 125.0 (107.0–139.0) 128.5 (110.0–142.0) 122.0 (105.0–137.0) 117.5 (97.0–129.5) <0.001
RDW, % 14.3 (13.2–15.9) 14.0 (13.0–15.6) 15.3 (13.3–17.0) 15.0 (13.7–16.4) <0.001
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cose levels (–0.02, 95% CI –0.20 to 0.16, p = 0.796). As far 
as hematological parameters were concerned, there was 
a significant correlation between nutritional risk and he-
moglobin levels (–0.50, 95% CI –0.67 to –0.32, p < 0.001) 
as well as RDW (0.46, 95% CI 0.28–0.63, p < 0.001). He-
mostatic parameters, namely platelet counts (–0.06, 95% 
CI –0.24 to 0.12, p = 0.506) and INR (0.15, 95% CI –0.05 
to 0.35, p = 0.143), were not significantly associated with 
the NRS score. After stepwise adjustment for demo-
graphics (Model 1), comorbidities (Model 2) and main 
diagnosis (Model 3), these associations remained robust. 
Only CRP levels ceased to be significantly correlated with 
NRS scores after adjustment for comorbidities (0.13, 
95% CI –0.06 to 0.31, p = 0.179). Levels of PCT showed 
marginal insignificance in Model 2 (0.18, 95% CI 0.00–
0.36, p  = 0.050) but regained significance in Model 3 
(0.20, 95% CI 0.03–0.37, p = 0.025). Detailed results are 
displayed in  table 2 .
 Association of Acute and Chronic Malnutrition with 
Biomarker Levels 
 Subgroup analyses revealed that only acutely mal-
nourished patients had significant associations between 
nutritional risk and CRP levels (0.92, 95% CI 0.18–1.67, 
p = 0.015), proADM (0.88, 95% CI 0.14–1.62, p = 0.021), 
copeptin (0.84, 95% CI 0.10–1.59, p = 0.027), creatinine 
(0.91, 95% CI 0.17–1.66, p = 0.016), vitamin D25 (–0.87, 
95% CI –1.61 to –0.12, p = 0.022) and glucose (0.81, 95% 
CI 0.07–1.55, p = 0.033). Patients with chronic impair-
ment of nutritional status showed no significant associa-
tions with biomarkers of inflammation/infection, renal 
function, stress or nutritional status. Only 2 parameters 
of hematological function, platelets (1.13, 95% CI 0.32–
1.95, p = 0.006) and RDW (0.88, 95% CI 0.06–1.70, p = 
0.036) were significantly associated with NRS scores in 
these patients. Detailed results are presented in  table 3 .
 Discussion 
 We found strong associations between nutritional 
status and biomarkers from multiple pathophysiological 
states, including inflammation/infection, stress and kid-
ney and hematological function. Compared within the 
different NRS score categories, patients at risk nutrition-
ally had more pronounced alterations of biomarker lev-
els. This was confirmed through linear regression analy-
ses adjusted for different confounding factors. Although 
observational studies may not prove causality, our re-
sults support the hypothesis that the adverse outcomes 
often seen in malnourished patients are linked through 
these pathways.
Table 2.  Association between NRS scores and biomarkers (transformed into deciles), adjusted for age/gender (Model 1), age/gender/
comorbidities (Model 2) and age/gender/comorbidities/main diagnosis (Model 3)
  Unadjusted Model 1 Model 2  Model 3
coefficient (95% CI) p value coefficient (95% CI) p value coefficient (95% CI) p value coeffi cient (95% CI) p value
Inflammation/infection
CRP, mg/l 0.21 (0.03 to 0.39) 0.021 0.26 (0.07 to 0.44) 0.006 0.13 (–0.06 to 0.31) 0.179 0.13 (–0.05 to 0.31) 0.171
PCT, μg/l 0.28 (0.10 to 0.47) 0.003 0.27 (0.08 to 0.46) 0.005 0.18 (0.00 to 0.36) 0.050 0.20 (0.03 to 0.37) 0.025
WBC, 109/l –0.04 (–0.22 to 0.14) 0.630 –0.05 (–0.24 to 0.13) 0.567 0.02 (–0.17 to 0.22) 0.808 0.01 (–0.19 to 0.21) 0.923
Albumin, g/l –0.60 (–0.77 to –0.43) <0.001 –0.59 (–0.76 to –0.41) <0.001 –0.45 (–0.63 to –0.27) <0.001 –0.39 (–0.57 to –0.21) <0.001
ProADM, nmol/l 0.40 (0.23 to 0.58) <0.001 0.26 (0.09 to 0.43) 0.003 0.25 (0.09 to 0.40) 0.002 0.28 (0.12 to 0.43) 0.001
Stress
Copeptin, pmol/l 0.44 (0.27 to 0.62) <0.001 0.28 (0.11 to 0.45) 0.001 0.31 (0.14 to 0.48) <0.001 0.34 (0.17 to 0.51) <0.001
Renal function
Creatinine, μmol/l –0.04 (–0.22 to 0.14) 0.653 –0.15 (–0.33 to 0.03) 0.094 –0.03 (–0.18 to 0.12) 0.693 0.02 (–0.12 to 0.16) 0.791
Urea, mmol/l 0.28 (0.10 to 0.46) 0.002 0.11 (–0.06 to 0.29) 0.197 0.19 (0.04 to 0.35) 0.013 0.23 (0.07 to 0.38) 0.004
Nutritional status
Vitamin D25, nmol/l –0.23 (–0.41 to –0.05) 0.012 –0.19 (–0.37 to 0.00) 0.046 –0.22 (–0.41 to –0.02) 0.027 –0.22 (–0.41 to –0.02) 0.031
Calcium, corrected, mmol/l 0.43 (0.26 to 0.61) <0.001 0.40 (0.22 to 0.59) <0.001 0.32 (0.13 to 0.51) 0.001 0.29 (0.10 to 0.49) 0.002
Glucose, mmol/l –0.02 (–0.20 to 0.16) 0.796 –0.09 (–0.28 to 0.09) 0.312 –0.08 (–0.27 to 0.10) 0.380 –0.07 (–0.26 to 0.12) 0.454
Hematological function
Platelets, /mm3 –0.06 (–0.24 to 0.12) 0.506 –0.09 (–0.27 to 0.10) 0.354 –0.07 (–0.26 to 0.12) 0.489 –0.08 (–0.28 to 0.11) 0.403
INR 0.15 (–0.05 to 0.35) 0.143 0.06 (–0.14 to 0.26) 0.568 0.14 (–0.07 to 0.35) 0.194 0.13 (–0.08 to 0.34) 0.222
Hemoglobin, g/l –0.50 (–0.67 to –0.32) <0.001 –0.48 (–0.66 to –0.30) <0.001 –0.29 (–0.45 to –0.12) 0.001 –0.27 (–0.43 to –0.10) 0.002
RDW, % 0.46 (0.28 to 0.63) <0.001 0.40 (0.22 to 0.58) <0.001 0.28 (0.10 to 0.46) 0.003 0.26 (0.07 to 0.44) 0.006
Bold values denote significant results.
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 To evaluate the risk for malnutrition, we used the NRS 
2002, a screening tool whose use has shed light on adverse 
clinical outcomes associated with malnutrition across 
multiple patient populations  [11] . We also asked the ques-
tion as to which among acute and chronic malnutrition 
had stronger associations with adverse outcomes. We 
found the association to be stronger with acute malnutri-
tion, defined as reduced nutritional intake within the last 
7 days. An International Consensus Guideline Committee 
constituted to develop a  consensus approach to defining 
malnutrition syndromes for adults in the clinical setting 
proposed an etiology-based definition of malnutrition 
 [12] . The Academy of Nutrition and Dietetics and the 
American Society for Parenteral and Enteral Nutrition 
therefore introduced 3 malnutrition categories based on 
underlying cause, with the categories including malnutri-
tion in the context of (a) social and environmental circum-
stances, (b) chronic illness and (c) acute illness or inju-
ry  [13] . Our results showing differences in biomarker lev-
els in patients with acute versus chronic malnutrition 
support these definition categories and suggest that 
 different pathophysiological pathways are activated in 
each of these categories. This is especially true in the case 
of markers of inflammation, which reflect moderate in-
flammatory reactions in chronically ill patients and a 
strongly activated inflammatory system in acutely ill pa-
tients. Whether these findings also have therapeutic impli-
cations remains to be investigated in interventional trials.
 Perspectives from Other Studies 
 Multiple studies have reported an association between 
nutritional impairment and inflammation as measured 
using CRP levels. Earlier studies have found that malnu-
trition as assessed by the patient-generated subjective 
global assessment  [14, 15] and the Mini-Nutritional As-
sessment and weight loss  [16] was associated with higher 
levels of CRP. However, the methods used to assess nu-
tritional status differed from those in our study. Our 
study confirms this association using another screening 
tool (NRS 2002) and looking at additional biomarkers of 
inflammation such as PCT and proADM. Importantly, 
the multivariate models revealed that the association be-
tween NRS scores and CRP was no longer significant, 
which suggests that CRP is mainly influenced by disease 
severity and age, and that malnutrition per se affects it to 
a lesser extent.
 To our knowledge, this is the first report evaluating the 
association between NRS scores and copeptin, a marker 
Table 3.  Association between NRS scores and biomarkers (transformed into deciles); subgroup analysis of acute vs. chronic  malnutrition
 Acute malnutrition Chronic malnutrition
 coefficient (95% CI) p value coefficient (95% CI) p value
Inflammation/infection
CRP, mg/l 0.92 (0.18 to 1.67) 0.015 –0.07 (–0.89 to 0.74) 0.858
PCT, μg/l 0.69 (–0.08 to 1.46) 0.078 0.16 (–0.68 to 1.01) 0.704
WBC, 109/l –0.73 (–1.48 to 0.01) 0.054 0.69 (–0.12 to 1.51) 0.096
Albumin, g/l –0.39 (–1.13 to 0.36) 0.306 –0.16 (–0.97 to 0.66) 0.703
ProADM, nmol/l 0.88 (0.14 to 1.62) 0.021 0.50 (–0.31 to 1.32) 0.226
Stress
Copeptin, pmol/l 0.84 (0.10 to 1.59) 0.027 0.25 (–0.57 to 1.07) 0.547
Renal function
Creatinine, μmol/l 0.91 (0.17 to 1.66) 0.016 0.10 (–0.72 to 0.92) 0.807
Urea, mmol/l 0.29 (–0.46 to 1.04) 0.446 0.21 (–0.61 to 1.03) 0.615
Nutritional status
Vitamin D25, nmol/l –0.87 (–1.61 to –0.12) 0.022 –0.18 (–1.00 to 0.63) 0.660
Calcium, corrected, mmol/l –0.25 (–1.00 to 0.50) 0.517 0.48 (–0.34 to 1.30) 0.252
Glucose, mmol/l 0.81 (0.07 to 1.55) 0.033 0.28 (–0.53 to 1.09) 0.499
Hematological function
Platelets, /mm3 –0.68 (–1.43 to 0.07) 0.076 1.13 (0.32 to 1.95) 0.006
INR 0.69 (–0.14 to 1.51) 0.102 0.40 (–0.50 to 1.30) 0.382
Hemoglobin, g/l –0.53 (–1.27 to 0.22) 0.165 –0.23 (–1.05 to 0.59) 0.581
RDW, % 0.40 (–0.35 to 1.15) 0.300 0.88 (0.06 to 1.70) 0.036
Bold values denote significant results.
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of stress  [17] . Copeptin is part of pre-pro-vasopressin, a 
precursor of vasopressin, and is influenced by volume, 
osmotic and stress stimuli. Of note, we did not assess flu-
id/volume status in our cohort and therefore could not 
differentiate which stimulus may have been most impor-
tant in increasing copeptin levels in patients with elevated 
NRS scores  [18] .
 A study conducted by Tufan et al.  [19] found that in 
addition to routinely used markers of malnutrition, the 
urea/creatinine ratio may provide additional informa-
tion on malnutrition in a population of hemodialysis pa-
tients. Our findings indicating significant association of 
malnutrition with urea but not with creatinine support 
that hypothesis. However, the increase in urea may well 
be a sign of protein catabolism in these malnourished 
patients.
 Specific nutritional markers would be very important 
in improving malnutrition screening. Much attention has 
been paid to albumin levels as a putative nutritional 
marker. Historically, albumin was considered as a nutri-
tional marker because of its decrease in patients with se-
vere protein malnutrition and Kwashiorkor, but today 
the association between malnutrition and albumin is 
questioned, with albumin being viewed instead as a nega-
tive acute phase protein  [20] , for which reason we have 
included albumin with the markers of inflammation.
 In regard to lower hemoglobin levels, the higher prev-
alence of anemia in malnourished patients is in line with 
previous research and may be partly explained by the in-
flammatory reaction and by decreased production of he-
moglobin due to low substrate levels  [21] .
 Methodological Aspects 
 A strength of the present study is the number of clini-
cal biomarkers associated with different pathophysiolog-
ical states that were evaluated. An additional strength is 
the use of the NRS 2002 as a screening tool. The NRS 2002 
is an evidence-based and extensively used screening tool 
that has been validated and is recommended by the 
 ESPEN as being suitable for use in screening adult inpa-
tients  [3, 20] .
 Our study has some limitations. First, the heterogene-
ity of patients suffering from acute or chronic malnutri-
tion introduces significant variability into the statistical 
models. Second, we used NRS 2002 as a surrogate for mal-
nutrition but performed no further detailed assessments 
of nutritional status. The NRS 2002 is a nutritional screen-
ing tool and not all patients with increased risk as assessed 
by the NRS may have clinical malnutrition. Third, we 
only assessed initial biomarker levels; whether biomarker 
kinetics are influenced by malnutrition status or disease 
severity remains unclear. Finally, this study does not 
prove causality between malnutrition and biomarker lev-
els despite adjustment for different potentially confound-
ing factors. This relationship should be investigated in 
further interventional studies exploring the effect of nu-
tritional therapy on biomarkers.
 Clinical Implications 
 Our study revealed that increasing age and malig-
nancies were significantly associated with malnutrition 
whether they were primary diagnoses or comorbidities. 
This finding, combined with the knowledge of the 
 number of elderly patients or patients with tumors 
who are hospitalized will enable a more accurate estima-
tion of the true burden of malnutrition in hospitalized 
patients than is currently available. Awareness of the 
true burden of malnutrition in this patient population 
may prompt proactive assessment of nutritional status 
immediately upon admission and thereby facilitate the 
timely implementation of interventions to address mal-
nutrition in patients at risk (e.g. the elderly or those with 
 tumors).
 Combining patient history with information on the 
levels of biomarkers shown to be significantly associated 
with malnutrition in our study (e.g. CRP, PCT, pro-
ADM, copeptin, albumin, corrected calcium, hemoglo-
bin, and RDW) may assist with risk stratification, early 
identification of patients at risk for malnutrition, timely 
institution of appropriate interventions and follow-up 
of responses to these interventions. Given that levels of 
many of these biomarkers are routinely assessed at ad-
mission or can be obtained without too much difficulty, 
assessment of nutritional status should not prove to be 
a significant problem. Interventions to address nutri-
tional deficiencies have the potential to significantly im-
prove clinical outcomes through their possible impact 
on lengths of stay, readmission rates and mortality. Fu-
ture studies exploring the impact of proactive assess-
ment of nutritional status and timely implementation of 
appropriate interventions on these parameters may be 
informative  [22] .
 Conclusion 
 Acute malnutrition was associated with a pronounced 
inflammatory response and an alteration in levels of bio-
markers associated with different pathophysiological 
states. Interventional trials are needed to prove causality.
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